Notable Labs, Ltd. (NTBL) - Uzoq muddatli qarzning kapitalga nisbati

Notable Labs, Ltd. (NTBL) narxining evolyutsiyasini aks ettiruvchi ushbu grafik FDA va CLIA talablarining qat'iyligidan kelib chiqadigan biznes murakkabliklarini, shuningdek, PPMP AI tizimi uchun yuqori ishlab chiqish xarajatlarini ko'rsatadi, bunda ko'rsatkich 0.00 darajasida turibdi. Masshtablash modeli klinikalar uchun analitikaga bulutli kirish imkoniyatiga tayanadi, bu esa muassasalarning o'z laboratoriyalarini tashkil etishga bo'lgan ehtiyojini yo'qotadi. O'sish potentsiali biotexnologiya sektorining aniq terapiya prognozlash vositalariga bo'lgan tobora ortib borayotgan qiziqishiga asoslangan.

Notable Labs Inc. - NTBL Uzoq muddatli qarzning kapitalga nisbati (davr: 21.02.2024 - 02.11.2024)

Notable Labs, Ltd. kompaniyasining tahliliy kesimlari

- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari Notable Labs Ltd|NTBL - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi ko'rsatkichlari:
Bozor kapitallashuvi Notable Labs, Ltd.|NTBL - Kompaniyaning to‘liq qiymati
- kompaniyaning balans qiymati tafsilotlari:
Bitta aksiya hisobiga xususiy kapital Notable Labs|NTBL - Balans kapitallashuvi|Kapitallashuvning sof aktivlarga nisbati notablelabs.com|NTBL - Kompaniyaning umumiy aktivlari
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning kapitalga nisbati Notable Labs, Ltd.|NTBL - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati notablelabs.com|NTBL - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Notable Labs, Ltd.|NTBL - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli majburiyatlari Notable Labs|Tezkor likvidlik koeffitsiyenti notablelabs.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
NTBL - Kompaniyaning sof foydasi
Kompaniyaning umumiy tahlili:Notable Labs Ltd - NTBL

Notable Labs , Ltd. (NTBL) sog'liqni saqlash gigantlari uchun sun'iy intellekt dasturlari va o'zining terapevtik ishlanmalari orqali daromadlarini diversifikatsiya qilmoqda. GURU.Markets platformasida uzoq muddatli qarzdorlikning kapitalga nisbati profilini tahlil qilish orqali investorlar biznesning tashqi qarzga qanchalik bog'liqligini ko'rishlari mumkin. Ushbu ko'rsatkich bir yildan ortiq muddatli majburiyatlarni kompaniyaning sof aktivlari bilan solishtiradi. Bu moliyaviy barqarorlikni va haddan tashqari kredit yuklamasi xavfini baholash imkonini beradi. Barqaror ko'rsatkich kengayish strategiyasining asoslanganligini tasdiqlaydi.

Muhim raqobatchilar

Uzoq muddatli qarzning o'z kapitaliga nisbati BeiGene Ltd. (ONC)|Uzoq muddatli qarzning kapitalga nisbati HALO|Uzoq muddatli qarzning kapitalga nisbati Revolution Medicines Corp (RVMD)|Uzoq muddatli qarzning o'z kapitaliga nisbati Ascentage Pharma Group AAPG|CGON: Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|UroGen Pharma - Uzoq muddatli qarzning kapitalga nisbati|Bicara Therapeutics Inc (BCAX) - Uzoq muddatli qarzning o'z kapitaliga nisbati|PSNL: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Erasca Oncology (ERAS)|Uzoq muddatli qarzning o'z kapitaliga nisbati Delcath Systems, Inc.|YMAB: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati AURA (Aura Biosciences)|CADL (candeltx.com) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati ARAY (Accuray Inc.)|SLS - Uzoq muddatli qarzning o'z kapitaliga nisbati|ACTU: Uzoq muddatli qarzning o'z kapitaliga nisbati|CTOR - Uzoq muddatli qarzning kapitalga nisbati|tuhurabio.com (HURA) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Protara Therapeutics Inc - Uzoq muddatli qarzning kapitalga koeffitsiyenti|FATE (Fate Therapeutics Corp) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Aadi Bio WHWK|Uzoq muddatli qarzning o'z kapitaliga nisbati TScan Therapeutics (TCRX)|championsoncology.com - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Uzoq muddatli qarzning o'z kapitaliga nisbati XBiotech XBIT|CEL-SCI Corp. (CVM) - Uzoq muddatli majburiyatlarning kapitalga nisbati|OSTX: Uzoq muddatli qarzning o'z kapitaliga nisbati|Radiopharm Theranostics Ltd - Uzoq muddatli kreditlarning kapitalga nisbati|ARTV: Uzoq muddatli qarzning kapitalga nisbati|Adlai Nortye (ANL) - Uzoq muddatli qarzning kapitalga nisbati|VERU (Veru) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati TPST|Uzoq muddatli qarzning o'z kapitaliga nisbati Xilio Therapeutics, Inc. (XLO)|Uzoq muddatli qarzning o'z kapitaliga nisbati RENB (renovarobio.com)|Uzoq muddatli qarzning kapitalga nisbati MURA (Mural Oncology)|Kairos Pharma Limited (KAPA) - Uzoq muddatli majburiyatlarning kapitalga nisbati|OKUR: Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti GDTC (CytoMed Therapeutics)|curis.com (CRIS) - Uzoq muddatli qarzning o'z kapitaliga nisbati|APLM (Apollomics) - Uzoq muddatli qarzning o'z kapitaliga nisbati|THAR (Tharimmune, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning kapitalga nisbati Advanced Biomed Corp|Uzoq muddatli qarzning kapitalga nisbati GNPX|Uzoq muddatli qarzning o'z kapitaliga nisbati CLDI (calidibio.com)|Uzoq muddatli qarzning o'z kapitaliga nisbati Sunshine Biopharma SBFM|Uzoq muddatli qarzdorlikning kapitalga nisbati Xenetic Biosciences Inc. (XBIO)|SLRX: Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti PPBT (purple-biotech.com)|aoncology.com (AONC) - Uzoq muddatli qarzning o'z kapitaliga nisbati|BGNE (BeiGene Ltd.) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati CKPT|ELEV (Elevation Oncology Inc.) - Uzoq muddatli kreditlarning kapitalga nisbati|Uzoq muddatli qarzning kapitalga nisbati ICAD|ikenaoncology.com - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Viracta Therapeutics, Inc. - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzdorlikning kapitalga nisbati MorphoSys Inc (MOR)|NAYA - Uzoq muddatli qarzning o'z kapitaliga nisbati|AAPGV (Ascentage) - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi